Open an account

AbbVie

ABBV · NYSE

$289.08+$6.40 (+2.26%)TodayMarket closed ·
Prev close $282.68

About ABBV

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 57,000 full-time employees. The company went IPO on 2013-01-02. The company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).

Employees
57,000
Headquarters
North Chicago, Illinois
Listed
Jan 2, 2013
Sector
Health Care
Industry
Biotechnology
Website
abbvie.com

ABBV key statistics

Market cap
499.53B
Price-earnings ratio
79.85
Dividend yield
2.37%
Average volume
4.85M
Volume
3.80M
Open price
$286.90
High today
$290.98
Low today
$285.00
52 Week high
$291.40
52 Week low
$190.75

AbbVie (ABBV) at a glance

AbbVie (ABBV) last traded at $289.08, with a market cap of 499.53B, a price-to-earnings ratio of 79.85 and a dividend yield of 2.37%.

Today the stock has traded between $285.00 and $290.98. The current price is 1.4% above the day's low and 0.7% below its high.

Volume so far is 3.80M shares, below the average of 4.85M shares a day.

Over the past year AbbVie has ranged from $190.75 to $291.40, and now sits 98% of the way up that range.

AbbVie met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $3.65 per share against an estimate of $3.68.

The average analyst price target is $283.10, 2.1% below the current price, from 23 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

83%of 23 analyst ratings say Buy
  • Buy82.6%
  • Hold17.4%
  • Sell0.0%
Price target · 33 analystsAvg $283.10
Low
$199.02
Now
$289.08
High
$344.40

ABBV earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 0.9% on average.

  1. Q3 FY24: reported $3.00 per share against an estimate of $2.97
  2. Q4 FY24: reported $2.16 per share against an estimate of $2.16
  3. Q1 FY25: reported $2.46 per share against an estimate of $2.43
  4. Q2 FY25: reported $2.97 per share against an estimate of $2.94
  5. Q3 FY25: reported $1.86 per share against an estimate of $1.81
  6. Q4 FY25: reported $2.71 per share against an estimate of $2.71
  7. Q1 FY26: reported $2.65 per share against an estimate of $2.65
  8. Q2 FY26: reported $3.65 per share against an estimate of $3.68

ABBV news

  • Press releasePRNewswire

    AbbVie Named Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team, Launches AbbVie Race to Innovate to Support Immunology Community

  • Press releasePRNewswire

    AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Disease

  • Press releasePRNewswire

    AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio

  • Press releasePRNewswire

    /C O R R E C T I O N - AbbVie/

  • Press releasePRNewswire

    SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026

  • Press releasePRNewswire

    AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease

  • Vandana Singh

    Why is Alaunos Therapeutics Stock Trading 200% Higher on Tuesday?

  • Press releasePRNewswire

    New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease

Similar companies

Companies in the same industry as AbbVie

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.